SCHEMBL29333531

SCHEMBL29333531

C=CC(=O)N1[C@H](C)COC[C@H]1c1cc(Cl)cc(-c2ccnc(N)n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.38
DBF4 Q9UBU7 2/20 0.38
JAK2 O60674 4/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
CHEK1 O14757 1/20 0.35
ATR Q13535 1/20 0.35
PDCD1 Q15116 1/20 0.35
ATRIP Q8WXE1 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
KMO O15229 2/20 0.33
ROCK1 Q13464 1/20 0.33
CAMKK2 Q96RR4 1/20 0.33
KRAS P01116 3/20 0.33
BTK Q06187 1/20 0.33
CDK2 P24941 2/20 0.32
ROCK2 O75116 1/20 0.32
MAP4K4 O95819 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31008631 1.00 CDC7 (0.38) CDC7DBF4JAK2PDK1PDK2
SCHEMBL31008587 0.90 MAPT (0.35) KMOKRASBTK
SCHEMBL29333529 0.90 MAPT (0.35) KMOKRASBTK
SCHEMBL29336222 0.87 CDC7 (0.36) CDC7DBF4JAK2KMOCAMKK2
SCHEMBL29333804 0.87 CDC7 (0.36) CDC7DBF4JAK2KMOCAMKK2
SCHEMBL30855104 0.87 CDC7 (0.36) CDC7DBF4JAK2KMOCAMKK2
SCHEMBL30855060 0.86 CHEK1 (0.35) CDC7JAK2PDK1PDK2PDK3
SCHEMBL29333574 0.86 CHEK1 (0.35) CDC7JAK2PDK1PDK2PDK3
SCHEMBL31008605 0.85 KRAS (0.33) KRAS
SCHEMBL29333521 0.85 KRAS (0.33) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 CDC7 991/4885DBF4 957/4885JAK2 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.